Navigation Links
MultiCell and University Health Network Will Evaluate Two Potential Therapies for Liver Cancer Treatment
Date:7/11/2011

WOONSOCKET, R.I., July 11, 2011 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) ("MultiCell") today announced that it entered into a sponsored research agreement with University Health Network pursuant to which Anand Ghanekar, M.D., Ph.D., of the University Health Network's Toronto General Hospital, will direct research activities relating to the evaluation of MultiCell's product candidates MCT-465 and MCT-485, in in vitro models for the treatment of primary liver cancer.  The mechanism of action of MCT-465 and MCT-485 and their potential selective effect on liver cancer stem cells will also be evaluated.  

The role of liver stem cells in the carcinogenic process has led researchers to hypothesize that primary liver cancer arises by maturation arrest of liver stem cells.  While progress has been made in developing cancer therapies that result in cytoreduction, the control of cancer over a longer interval and especially of metastatic disease remains a key goal.  Cancer stem cells are believed to be responsible for cancer relapse by being less sensitive to conventional therapies.  MultiCell owns exclusive rights to several issued U.S. patents and corresponding foreign patents related to the isolation and differentiation of liver stem cells.  

Primary liver cancer resulting from Hepatitis B and Hepatitis C infection is the most common cancer in the world with more than 1 million new cases diagnosed each year.  Primary liver cancer is rarely discovered early and often does not respond to treatment.

"We are pleased to have the opportunity to work with Dr. Ghanekar and his colleagues at Toronto General Hospital," said W. Gerald Newmin, Chairman and Chief Executive Officer of MultiCell.  "Dr. Ghanekar is one of the leading researchers in the field of liver cancer, and we are hopeful MCT-465 and MCT-
'/>"/>

SOURCE MultiCell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
2. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
3. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
4. MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial
5. MultiCell Technologies Launches New Web Site
6. MultiCells Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets
7. MultiCell Technologies is Granted Stem Cell Patent
8. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
9. Boston University Biomedical Engineers Find Chink in Bacterias Armor
10. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
11. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 Remedy Informatics, ... healthcare and life sciences research, today announced it ... (GSA) IT Schedule 70 supply contract (GS-35F-367AA, effective ... provide innovative IT solutions to government agencies at ... this contract, Remedy has placed its products and ...
(Date:6/18/2013)... June 18, 2013  Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a general corporate update in conjunction with ... Tuesday, June 25 at 2:10 p.m. Pacific Time in ... the meeting is as follows: 2:00 p.m. – 2:10 p.m. ... of April 26, 2013) 2:10 p.m. – 3:15 p.m. Corporate ...
(Date:6/17/2013)... , June 17, 2013  Hanger, Inc. (NYSE:  HGR) ... agreement that increases its senior secured facilities to an ... previously.  The new credit agreement includes a $200 million ... facility.  The previous credit agreement was comprised of a ... term loan.  Each new facility matures on June 17, ...
Breaking Medicine Technology:Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 3
... Matrox Graphics Inc., the leading manufacturer of specialized graphics ... the Matrox Xenia(TM) display controller boards ... workstations . The software suite contains a number ... including Radiology Information System (RIS), Picture Archiving and Communication ...
... FOREST, Ill., Oct. 29 Today Hospira, Inc. (NYSE: ... analgesia (PCA) infusion system. Introduced in 1984, Hospira,s PCA was ... was a simple concept: patients know best when they are ... medication. Over the past 25 years, PCA technology has improved ...
Cached Medicine Technology:Rogan-Delft Approves Matrox Xenia Series for Use With Zillion Suite 2Rogan-Delft Approves Matrox Xenia Series for Use With Zillion Suite 3Healthcare Industry Celebrates 25 Years of Advanced Pain Management With PCA Infusion System 2Healthcare Industry Celebrates 25 Years of Advanced Pain Management With PCA Infusion System 3Healthcare Industry Celebrates 25 Years of Advanced Pain Management With PCA Infusion System 4
(Date:6/18/2013)... Sun Buick GMC, Moosic, is sponsoring the ... Annual Golf Tournament on Thursday, June 20, at Irem Country ... a 2013 Buick Verano and will go to the lucky ... Irem’s 7th hole. , The MFHS golf tournament is open ... person captain and crew team for 18 holes. The fee ...
(Date:6/18/2013)... cancer cells have a much different and more ... The University of Texas at Dallas have found that ... combat lung cancer. , In an article published online ... UT Dallas researchers compared the metabolic characteristics of non-small-cell ... the same patient. , They found that the ...
(Date:6/18/2013)... Researchers have discovered and mapped the signaling network ... if broken, could cut off cancer cell growth at ... at The University of Texas MD Anderson Cancer Center ... a well-known cancer drug target, and MCM7, a protein ... the June issue of Cancer Cell . , ...
(Date:6/18/2013)... The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) joined ... Emergency Plan for AIDS Relief (PEPFAR) to mark PEPFAR’s ... the global effort to eliminate pediatric HIV/AIDs. U.S. ... June 2013, one million babies globally have been born ... in 2003, EGPAF has been a key implementer of ...
(Date:6/18/2013)... 2013 Healthcare Solutions , ... Procura Management, today announced the appointment of Richard ... In this position, Leonardo will direct Healthcare Solutions’ ... strategic growth initiatives. , Recognized in the property ... Leonardo brings more than 20 years of experience ...
Breaking Medicine News(10 mins):Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3Health News:Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer 2
... Department of Orthopaedic Surgery at the University of Pittsburgh School of ... Center (UPMC) for Sports Medicine will be installed as the 37th ... Saturday, July 12, 2008, during the Society,s Annual Meeting in Orlando, ... ...
... NASHVILLE, Tenn., July 2 Ambulatory Services of,America, ... Dallas, LLP, its,sixth joint venture to provide outpatient ... joint venture between ASA,s subsidiary, Radiation,Oncology Services of ... Landmark,Radiation Dallas LP. ROSA of North Dallas will ...
... Senate, derailing a critical bipartisan bill that would have ... to physicians who,treat Medicare patients, and made significant improvements ... Last week, Sen. Richard Lugar joined a minority of ... people on Medicare continued,access to their doctors and improved ...
... childbirth as most common reason for hospitalizations, analysis finds ... more than 1.2 million Americans -- roughly equivalent to ... a federal government analysis of hospital admissions and costs ... the most common reason for admission to hospital, and ...
... company with an outstanding track record in the ... technologies, announced availability of the Genomatix Genome Analyzer ... first integrated hardware / software solution for in-depth ... (NGS) devices as provided by Illumina, Roche (454), ...
... simplex out of hiding could bring about a cure, scientists ... Americans are afflicted by breakouts of unsightly cold sores, caused ... finally offering them the possibility of a cure. , Scientists ... herpes simplex 1 slips into dormancy and stays dormant -- ...
Cached Medicine News:Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 2Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 3Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 4Health News:Ambulatory Services of America, Inc. Announces Joint Venture to Operate Radiation Oncology Facility in Dallas, Texas 2Health News:Indiana State Medical Association and AARP Urge Reconsideration of Bill to Protect Seniors' Access to Doctors and Improve Medicare 2Health News:Indiana State Medical Association and AARP Urge Reconsideration of Bill to Protect Seniors' Access to Doctors and Improve Medicare 3Health News:Next generation data analysis for next generation sequencing data 2Health News:New Hope Against the Cold Sore Virus 2Health News:New Hope Against the Cold Sore Virus 3
... establish the patient reportable range and establish ... Linearity is available in five-vial sets with ... 3700 and 4000; Bayer ADVIA 120; Coulter ... 755; Sysmex R-3000, R-3500, R-1000, RAM-1, XE-2100 ...
... CVA for CELL-DYN are assayed linearity control ... and to verify patient reportable range of ... also measure the linear performance of the ... have customized ranges appropriate for each instrument ...
... red blood cell (nRBC) control for evaluating the ... 755 hematology analyzer in its enumeration of the ... LH 750/LH 755. nRBC-Chex for LH is a ... for LH has a 75-day closed-vial stability and ...
... Sickle-Chex is a positive and negative whole ... of Hemoglobin S in solubility tests and ... SICKLEDEX and other manufacturers' solubility kits. ... squeeze dropper vial. The vial dispenses an ...
Medicine Products: